From decoy DNA sequences to plasmapheresis, researchers are testing strategies to get around anti-AAV antibodies that hinder ...

We recently published a list of Billionaire Glenn Russell Dubin’s 10 Stock Picks with Huge Upside Potential. In this article, ...

A devastating disease that's rare, fatal, and until now untreatable. How a new therapy may give kids a better life.

We recently compiled a list of the 11 Stocks That Will Bounce Back According To Analysts. In this article, we are going to ...

Sarepta Therapeutics, Inc.’s SRPT share price has surged by 6.43%, which has investors questioning if this is right time to sell.

Investors should be wary of biotech stocks. Sarepta Therapeutics (SRPT) lost 21.45% yesterday and lost nearly 70% of its ...

We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited content, log in or register for free.

The FDA's decision to appoint Vinay Prasad, MD, MPH, to head its Center for Biologics Evaluation and Research (CBER) raised ...

Sarepta stock plummeted Wednesday on a "double whammy" that includes its trimmed 2025 sales outlook and a critical Food and ...

The U.S. Food and Drug Administration (FDA) has chosen Dr. Vinay Prasad, a professor at the University of California-San ...

Uncertainty around ELEVIDYS sales impact Sarepta Therapeutics, Inc. Click here to find out why I downgraded SRPT stock to a ...

Sarepta Therapeutics Q1 2025 revenue beat expectations, but EPS missed, and cash reserves dropped significantly. Click here ...